CO2020014167A2 - Cell-Docking Antibody Fusion Constructs - Google Patents

Cell-Docking Antibody Fusion Constructs

Info

Publication number
CO2020014167A2
CO2020014167A2 CONC2020/0014167A CO2020014167A CO2020014167A2 CO 2020014167 A2 CO2020014167 A2 CO 2020014167A2 CO 2020014167 A CO2020014167 A CO 2020014167A CO 2020014167 A2 CO2020014167 A2 CO 2020014167A2
Authority
CO
Colombia
Prior art keywords
antigen
binding
cd16a
cell
docking
Prior art date
Application number
CONC2020/0014167A
Other languages
Spanish (es)
Inventor
Michael Tesar
Kristina Ellwanger
Ivica Fucek
Uwe Reusch
Thorsten Ross
Joachim Koch
Erich Rajkovic
Martin Treder
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of CO2020014167A2 publication Critical patent/CO2020014167A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a proteínas multiespecíficas de unión al antígeno que se acoplan a células natural killer (NK) para desencadenar la citotoxicidad de células NK al acoplarse al CD16A (FcRIIIA) expresado en células NK, en donde la proteína de unión al antígeno comprende al menos dos porciones de unión al antígeno CD16A y al menos una porción de unión al antígeno diana adicional. La porción de unión al antígeno CD16A comprende regiones variables de la cadena liviana y cadena pesada ligadas una después de la otra en una cadena de polipéptido y la región variable en el terminal N de la cadena de polipéptido que comprende la porción de unión al antígeno CD16A es una región variable de la cadena liviana.The invention relates to multispecific antigen-binding proteins that bind to natural killer (NK) cells to trigger NK cell cytotoxicity by binding to CD16A (FcRIIIA) expressed in NK cells, wherein the antigen-binding protein it comprises at least two CD16A antigen-binding portions and at least one additional target antigen-binding portion. The CD16A antigen-binding portion comprises heavy chain and light chain variable regions linked one after the other in a polypeptide chain and the N-terminal variable region of the polypeptide chain comprising the CD16A antigen-binding portion is a variable region of the light chain.

CONC2020/0014167A 2018-04-13 2020-11-12 Cell-Docking Antibody Fusion Constructs CO2020014167A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18167384 2018-04-13
EP18167385 2018-04-13
EP18190662 2018-08-24
EP18190661 2018-08-24
PCT/IB2019/053040 WO2019198051A2 (en) 2018-04-13 2019-04-12 Nk cell engaging antibody fusion constructs

Publications (1)

Publication Number Publication Date
CO2020014167A2 true CO2020014167A2 (en) 2021-04-08

Family

ID=66625219

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0014167A CO2020014167A2 (en) 2018-04-13 2020-11-12 Cell-Docking Antibody Fusion Constructs

Country Status (20)

Country Link
US (2) US11001633B2 (en)
EP (1) EP3774914A2 (en)
JP (1) JP2021521275A (en)
KR (1) KR20200143436A (en)
CN (3) CN113817066A (en)
AU (1) AU2019252970A1 (en)
BR (1) BR112020020828A2 (en)
CA (1) CA3095373A1 (en)
CL (2) CL2020002625A1 (en)
CO (1) CO2020014167A2 (en)
CR (1) CR20200549A (en)
IL (1) IL277925A (en)
MA (1) MA52227A (en)
MX (1) MX2020010728A (en)
PE (1) PE20201346A1 (en)
PH (1) PH12020551664A1 (en)
RU (1) RU2022105827A (en)
SG (1) SG11202010064QA (en)
TW (1) TW202012441A (en)
WO (1) WO2019198051A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115066274A (en) * 2019-09-25 2022-09-16 斯图加特大学 Trivalent binding molecules
US20230227559A1 (en) * 2019-12-10 2023-07-20 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
IL300314A (en) 2020-10-08 2023-04-01 Affimed Gmbh Trispecific binders
CA3200974A1 (en) * 2020-11-08 2022-05-12 Seagen Inc. Combination therapy
JP2023553384A (en) * 2020-12-03 2023-12-21 アムジエン・インコーポレーテツド Immunoglobulin constructs with multiple binding domains
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
CN116574190A (en) * 2021-07-30 2023-08-11 启愈生物技术(上海)有限公司 Antigen targeting, anti-CD 16A and immune effector cell activating three-function fusion protein and application thereof
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
CN113929785B (en) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 Chimeric antigen receptor immune cell capable of automatically secreting PD1-TREM2 bispecific antibody and application thereof
CA3233085A1 (en) * 2021-09-24 2023-03-30 Synergy Imt, Inc. Composition of recombinant antigen binding molecules and method of making and using thereof
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
AU2022382368A1 (en) 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders
CN116284385A (en) * 2021-12-07 2023-06-23 信达细胞制药(苏州)有限公司 P329G antibody targeting BCMA and combination and application of P329G antibody and chimeric antigen receptor cell
CN114349869B (en) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 Bispecific NK cell agonist, preparation method and application
WO2024027828A1 (en) * 2022-08-05 2024-02-08 Chimagen Biosciences, Ltd Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2004533997A (en) 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Antibodies that bind both BCMA and TACI
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP3141562A1 (en) 2009-03-10 2017-03-15 Biogen MA Inc. Anti-bcma antibodies
EP2361936B1 (en) * 2010-02-25 2016-04-20 Affimed GmbH Antigen-binding molecule and uses thereof
KR101972446B1 (en) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Bcma(cd269/tnfrsf17)-binding proteins
TWI679212B (en) * 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
US9676857B2 (en) 2012-03-16 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble engineered monomeric Fc
EP2869845B1 (en) * 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
US10189906B2 (en) 2012-11-01 2019-01-29 Max-Delrück-Centrum Für Molekulare Medizin Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh UNION MOLECULES FOR BCMA AND CD3
EP2970485A1 (en) * 2013-03-15 2016-01-20 Merck Patent GmbH Tetravalent bispecific antibodies
MX2016009050A (en) * 2014-01-15 2016-12-09 Zymeworks Inc Bi-specific cd3 and cd19 antigen-binding constructs.
IL286835B2 (en) * 2014-12-22 2024-03-01 Systimmune Inc Bispecific tetravalent antibodies and methods of makiing and using thereof
US20180318417A1 (en) * 2015-01-14 2018-11-08 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CA3219372A1 (en) * 2015-05-04 2016-11-10 Affimed Gmbh Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy
EP3091031A1 (en) * 2015-05-04 2016-11-09 Affimed GmbH Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
US10113003B2 (en) * 2015-06-23 2018-10-30 Innate Pharma Multispecific NK engager proteins
HUE050556T2 (en) * 2015-08-17 2020-12-28 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN105367660B (en) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 A kind of bispecific antibody of anti-CD16A antigen and anti-MUC1 antigen
CN106632681B (en) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 Anti- EGFR and AntiCD3 McAb bispecific antibody and its application
EP3589655B1 (en) * 2017-02-28 2022-10-26 Affimed GmbH Tandem-diabody for cd16a-directed nk-cell engagement

Also Published As

Publication number Publication date
CL2020002625A1 (en) 2021-02-19
AU2019252970A1 (en) 2020-11-26
CN112119097A (en) 2020-12-22
KR20200143436A (en) 2020-12-23
CN113880952A (en) 2022-01-04
US20200109202A1 (en) 2020-04-09
MA52227A (en) 2021-04-21
US20210253698A1 (en) 2021-08-19
PH12020551664A1 (en) 2021-12-13
SG11202010064QA (en) 2020-11-27
CL2023001085A1 (en) 2023-10-06
CN113817066A (en) 2021-12-21
CN112119097B (en) 2021-10-15
BR112020020828A2 (en) 2021-01-19
PE20201346A1 (en) 2020-11-25
CR20200549A (en) 2021-03-18
TW202012441A (en) 2020-04-01
JP2021521275A (en) 2021-08-26
IL277925A (en) 2020-11-30
US11001633B2 (en) 2021-05-11
WO2019198051A3 (en) 2019-11-14
RU2022105827A (en) 2022-04-05
WO2019198051A2 (en) 2019-10-17
EP3774914A2 (en) 2021-02-17
MX2020010728A (en) 2020-11-06
CA3095373A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
CO2020014167A2 (en) Cell-Docking Antibody Fusion Constructs
EA201491599A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
CL2019001001A1 (en) Bispecific heterodimeric fusion proteins containing fc yl-15 / yl-15ralpha fusion proteins and pd-1 antibody fragments.
CO6680656A2 (en) Antibodies to matrix metalloproteinase -9
PE20120549A1 (en) BISPECIFIC ANTIGEN BINDING PROTEINS
EA201491575A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
AR091069A1 (en) PROTEINS OF UNION TO ANTIGEN DIRECTED AGAINST THE ST2 RECEIVER
PE20190514A1 (en) BISPECIFIC ANTIBODY TYPE UNION PROTEINS THAT SPECIFICALLY JOIN CD3 AND CD123
AR079336A1 (en) ANTAGONISTS OF THE PRO-PROTEIN CONVERTASE-SUBTILISINE / TYPE 9 QUEXINE (PCSK9)
CL2013003090A1 (en) Polypeptide comprising a first amino acid sequence which in turn comprises at least one individual variable immunoglobulin domain that specifically binds to il-17f, il17-a / f, but not to il-17a, and a second amino acid sequence that it comprises at least one individual variable domain of immunoglobulin that specifically binds to il-17a, il-17f and il17-a / f; pharmaceutical composition that includes it; And its use.
ES2684475T3 (en) Proteins that bind to beta amyloid
WO2014144542A3 (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
EA201991912A1 (en) COMPOSITIONS CONTAINING PD-1-BINDING PROTEINS AND METHODS FOR PRODUCING THEREOF
MX2022016192A (en) Conditionally active anti-nectin-4 antibodies.
CO2020001654A2 (en) Antigen-binding proteins that bind to 5t4 and 4-1bb and related compositions and methods
AR114102A1 (en) ANTI-PD-1 / ANTI-HER2 NATURAL STRUCTURAL HETERODIMERIC BI-SPECIFIC ANTIBODY AND METHOD FOR ITS PREPARATION
MX2022009915A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof.
MX2021005048A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof.
AR093778A1 (en) BINDING PROTEINS OF ANTIGENO ANTI-HER3 / HER4 OF UNION TO FORK b OF HER3 AND TO FORK b OF HER4
MY198370A (en) Proteins specific for baff and b7rp1
BR112016019332A2 (en) innovative parent anti-human antibody
EA201691414A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9 AND METHODS OF THEIR APPLICATION
AR114285A1 (en) FUSION CONSTRUCTS OF THE ANTIBODY COUPLED TO NK CELLS
EA201690271A1 (en) CONSTRUCTIONS FOR EXPRESSION AND METHODS OF POLYPEPTIDE EXPRESSION IN EUKARYOT CELLS
EA202191187A1 (en) ANTIBODIES TO CTLA4, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND THEIR APPLICATION